PAULINA MENSAH: Open Payments
NPI 1568712958 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$579 in 30 payments from 15 companies in 2025. Trend: 2023 $240 · 2024 $69 · 2025 $579
Food & beverage: $579
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $86 |
| Lilly USA, LLC | 4 | $74 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| GlaxoSmithKline, LLC. | 3 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
| Averitas Pharma Inc. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Dynavax Technologies Corporation | 1 | $26 |
| Dexcom, Inc. | 1 | $22 |
Products named: Ozempic, Kerendia, REXULTI, MOUNJARO, SHINGRIX, JARDIANCE, QUTENZA, Heplisav-B.
Industry payments across TX — which companies pay providers there.
